Findings

What do systematic reviews say?

4,678 questions · 4,859 findings · 283 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,225 · 25.2%GRADE not reported 215 · 4.4%Very low 1,241 · 25.5%Low 1,210 · 24.9%Moderate 776 · 16%High 192 · 4%

Summary of findings for the main comparison: comprehensive care programmes vs usual care

ED visits · children with medical complexity

1 finding from 1 review

Comprehensive care programmes for children with medical complexity 2024 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 739 participants
Moderate

Summary of findings for the main comparison: comprehensive care programmes vs usual care

Duration of hospital admission (days) · children with medical complexity

1 finding from 1 review

Comprehensive care programmes for children with medical complexity 2024 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 739 participants
Moderate

Summary of findings for the main comparison: comprehensive care programmes vs usual care

Cost (healthcare-system perspective): total cost per patient (GBP) · children with medical complexity

1 finding from 1 review

Comprehensive care programmes for children with medical complexity 2024 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 739 participants
Low

Summary of findings for the main comparison: comprehensive care programmes vs usual care

Costs to the family · children with medical complexity

The review found no eligible studies for this question.

1 finding from 1 review

Comprehensive care programmes for children with medical complexity 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Survival · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1108 participants
High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Quality of life ‐ (EuroQol) EQ‐5D‐3L Index Score (total score): absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1061 participants
Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1139 participants
Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1134 participants
High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1134 participants
Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1108 participants
High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Time to first pulmonary exacerbation · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1108 participants
Moderate

Summary of findings 2. Octenidine‐dihydrochloride (OCT) hydrogel dressings vs OCT‐free placebo hydrogel dressings

Donor site healing time in days for adults · adults with skin graft donor sites

It is very uncertain whether summary of findings 2. Octenidine‐dihydrochloride (OCT) hydrogel… changes time to complete wound healing of skin graft donor sites (days)… compared with OCT‐free placebo hydrogel dressings (very low certainty).

1 finding from 1 review

Hydrogel dressings for donor sites of split‐thickness skin grafts 2023 · Cochrane Headline outcomes only
MD 0.4 [0.28, 0.52]
1 study · 41 participants
Very low

Summary of findings 2. Octenidine‐dihydrochloride (OCT) hydrogel dressings vs OCT‐free placebo hydrogel dressings

Donor site pain · adults with skin graft donor sites

The review found no eligible studies for this question.

1 finding from 1 review

Hydrogel dressings for donor sites of split‐thickness skin grafts 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings 2. Octenidine‐dihydrochloride (OCT) hydrogel dressings vs OCT‐free placebo hydrogel dressings

Health‐related quality of life · adults with skin graft donor sites

The review found no eligible studies for this question.

1 finding from 1 review

Hydrogel dressings for donor sites of split‐thickness skin grafts 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings 2. Octenidine‐dihydrochloride (OCT) hydrogel dressings vs OCT‐free placebo hydrogel dressings

Wound infection (bacterial colonisation) Measured using: contact cultures · adults with skin graft donor sites

1 finding from 1 review

Hydrogel dressings for donor sites of split‐thickness skin grafts 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low

Summary of findings 2. Octenidine‐dihydrochloride (OCT) hydrogel dressings vs OCT‐free placebo hydrogel dressings

Wound complications · adults with skin graft donor sites

The review found no eligible studies for this question.

1 finding from 1 review

Hydrogel dressings for donor sites of split‐thickness skin grafts 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings 2. Octenidine‐dihydrochloride (OCT) hydrogel dressings vs OCT‐free placebo hydrogel dressings

Adverse events · adults with skin graft donor sites

It is very uncertain whether summary of findings 2. Octenidine‐dihydrochloride (OCT) hydrogel… changes adverse events compared with OCT‐free placebo hydrogel dressings (very low certainty).

1 finding from 1 review

Hydrogel dressings for donor sites of split‐thickness skin grafts 2023 · Cochrane Headline outcomes only
RR 0.58 [0.06, 5.89]
1 study · 41 participants
Very low

Summary of findings for the main comparison: cough augmentation techniques vs no cough augmentation technique

Extubation successa · critically‐ill mechanically‐ventilated adults and children requiring extubation from mechanical ventilation

It is very uncertain whether summary of findings for the main comparison: cough augmentation… changes extubation successa compared with no cough augmentation technique (very low certainty).

1 finding from 1 review

Cough augmentation techniques for extubation or weaning critically ill patients from mechanical ventilation 2017 · Cochrane Headline outcomes only
RR 1.58 [1.13, 2.2]
1 study · 75 participants
Very low

Summary of findings for the main comparison: cough augmentation techniques vs no cough augmentation technique

Duration of mechanical ventilation · critically‐ill mechanically‐ventilated adults and children requiring extubation from mechanical ventilation

It is very uncertain whether summary of findings for the main comparison: cough augmentation… changes duration of mechanical ventilationb compared with no cough augmentation technique (very low certainty).

1 finding from 1 review

Cough augmentation techniques for extubation or weaning critically ill patients from mechanical ventilation 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 75 participants
Very low

Summary of findings for the main comparison: cough augmentation techniques vs no cough augmentation technique

ICU mortalitya · critically‐ill mechanically‐ventilated adults and children requiring extubation from mechanical ventilation

1 finding from 1 review

Cough augmentation techniques for extubation or weaning critically ill patients from mechanical ventilation 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 75 participants
Very low